000739SZSE

Progress Announcement on Guarantees for Subsidiaries

Apeloa Pharmaceutical Co., Ltd.··3 pages

✨ AI Summary

Prolo Pharmaceutical Co., Ltd. has provided guarantees totaling 30 million yuan for its wholly-owned subsidiary, Zhejiang Prolo Jiayuan Pharmaceutical Co., Ltd., through agreements with China Merchants Bank. The guarantees are for a 12-month term. The board of directors has approved these guarantees, which are deemed necessary for the subsidiary's operations and pose no significant financial risk to the company. The total external guarantee balance for subsidiaries now stands at 372.638 million yuan.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Overview of Guarantee Situation

  1. On February 3, 2026, Prolo Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") signed an "Irrevocable Guarantee Letter" (Contract No.: 571HT260202T00092801) with China Merchants Bank Jinhua Yiwu Branch ("China Merchants Bank"), agreeing to provide a joint liability guarantee for a working capital loan of 20 million yuan for its wholly-owned subsidiary, Zhejiang Prolo Jiayuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Jiayuan Pharmaceutical"). The guarantee period is 12 months.
  2. On February 4, 2026, the Company signed another "Irrevocable Guarantee Letter" (Contract No.: 571HT260203T00179801) with China Merchants Bank, agreeing to provide a joint liability guarantee for a working capital loan of 10 million yuan for Jiayuan Pharmaceutical. The guarantee period is also 12 months.

Review Procedures for Guarantee Matters

The Company held the 11th meeting of the 9th Board of Directors on March 7, 2025, and the 2024 Annual General Meeting on April 17, 2025, where it approved the proposal regarding the expected guarantees for subsidiaries, providing financing guarantees of up to 7.1 billion yuan for 10 subsidiaries and sub-subsidiaries from banks and other financial institutions. The authorization period for this external guarantee limit is from the date of approval at the 2024 Annual General Meeting until the date of the 2025 Annual General Meeting. For specific details, please refer to the announcements disclosed by the Company on March 11, 2025, and April 18, 2025, in the Securities Times and the Giant Tide Information Network.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.